Abstract
BackgroundIt is presently unclear what clinical pathways are followed for patients with non-metastatic PDAC in specialised centres for pancreatic surgery across the United Kingdom (UK).MethodsBetween August 2019 and August 2020 an electronic survey was conducted aiming at a national cohort of pancreatic surgeons in the UK. Participants replied to a list of standardised questions and clinical vignettes, and data were collected and analysed focusing on management preferences, resectability criteria, and contraindications to surgery.ResultsWithin the study period, 65 pancreatic surgeons from 27 specialist centres in the UK (96%) completed the survey. Multidisciplinary team meetings are utilised universally for the management of patients with PDAC, however, different staging systems for resectability classification are being applied. In borderline resectable PDAC, most surgeons were keen to proceed with surgical exploration post NAT, but differences were noted in preferred chemotherapy regimens. Surgeons from standard volume institutions performed fewer vein resections annually and were more likely to deem patients with locally advanced PDAC as unresectable. Intra-institutional variability in patient management was also present and ranging between 20-80%.ConclusionsSignificant variability in the surgical management of non-metastatic PDAC was identified both on inter- and intra-institutional level.
Highlights
Pancreatic adenocarcinoma (PDAC) remains a devastating disease with an extremely poor prognosis [1]
In borderline resectable PDAC, most surgeons were keen to proceed with surgical exploration post neoadjuvant/induction systemic treatment (NAT), but differences were noted in preferred chemotherapy regimens
Significant variability in the surgical management of non-metastatic PDAC was identified both on inter- and intra-institutional level
Summary
Pancreatic adenocarcinoma (PDAC) remains a devastating disease with an extremely poor prognosis [1]. In BR-PDAC, the introduction of neoadjuvant/induction systemic treatment (NAT) was based on its potential advantages: addressing occult micrometastatic disease in the preoperative setting, avoiding unnecessary surgery in tumours with aggressive biology, increasing the likelihood of R0 resection, and improving delivery rates of systemic treatment. Recent prospective trials have demonstrated a potential benefit in overall survival in patients with BR-PDAC who underwent NAT [12, 13], and emerging data suggest potential future practice changes. It is presently unclear what clinical pathways are followed for patients with non-metastatic PDAC in specialised centres for pancreatic surgery across the United Kingdom (UK)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.